EMA Authorised: Adcetris (Brentuximab vedotin) — Takeda Pharma A/S

View source ↗

Summary

EMA authorised Adcetris (brentuximab vedotin) for Hodgkin lymphoma and non-Hodgkin lymphoma, with Takeda Pharma A/S as the marketing authorisation holder; decis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Non-Hodgkin;Hodgkin Disease. MAH: Takeda Pharma A/S. Decision date: 18/02/2026